Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

SF3B1 Gene Mutations and Their Significance for Patients with Myelodysplastic Neoplasms (MDS)

Zuzana Zemanova, Tatiana Aghova, Halka Lhotska, Zuzana Vondrackova, Lucie Hodanova, Libuse Lizcova, Slavka Sotakova, Lubomir Minarik, Tomas Stopka, Anna Jonasova

Blood (2024) 144 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2024-202114

Published: 2024

Journal Articles

First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy

Anna Jonasova, Lubomir Minarik, Zuzana Zemanova, Helena Polackova, Tomas Stopka

Blood (2022) 140 (Supplement 1): 12311–12312.

https://doi.org/10.1182/blood-2022-169270

Published: 2022

Journal Articles

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Blood (2021) 138 (23): 2441–2445.

https://doi.org/10.1182/blood.2021012781

Published: 2021

Includes: Supplemental data

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Aleš Obr, MD PhD, Pavel Klener, Jr., Eva Kriegova, Dr, assoc prof, Zuzana Zemanova, PhD, Helena Urbankova, MSc, PhD, Andrea Jirkuvova, MD, Anna Petrackova, MSc, Barbora Cudova, Lenka Sedlarikova, MSc, VIT K Prochazka, MD, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3995.

https://doi.org/10.1182/blood-2019-123812

Published: 2019

Journal Articles

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Monika Hruba, Jitka Vesela, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, David Kundrat, Katarina Szikszai, PhD, Marie Lauermanova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 4230.

https://doi.org/10.1182/blood-2019-131150

Published: 2019

Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD

Blood (2018) 132 (Supplement 1): 42.

https://doi.org/10.1182/blood-2018-99-112437

Published: 2018

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Monika Hruba, MSc, Jitka Vesela, MSc, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, Katarina Szikszai, PhD, Marie Lauermannova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2018-99-118048

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Blood (2018) 132 (3): 264–276.

https://doi.org/10.1182/blood-2017-12-821363

Published: 2018

Includes: Supplemental data

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Kamila Polgarova, MD, Vojtech Kulvait, MSc, Karina Vargova, PhD, Lubomir Minarik, MD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 4294.

https://doi.org/10.1182/blood.V128.22.4294.4294

Published: 2016

Journal Articles

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD, Karla Svobodova, Halka Lhotska, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Lenka Pavlistova, PhD, Adela Berkova, PhD, Karolina Skipalova, Monika Belickova, PhD, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD PhD

Blood (2016) 128 (22): 1982.

https://doi.org/10.1182/blood.V128.22.1982.1982

Published: 2016

Journal Articles

Why Patients with 5q- Syndrome Have Thrombocythemia?

Vit Campr, MD PhD, Jan Stritesky, MD PhD, Ota Fuchs, PhD, Anna Jonasova, MD PhD, Zuzana Zemanova, PhD, Radana Neuwirtova, MD PhD

Blood (2016) 128 (22): 5533.

https://doi.org/10.1182/blood.V128.22.5533.5533

Published: 2016

Journal Articles

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

Zuzana Zemanova, Ass. Prof.,PhD, Kyra Michalova, PhD Prof., Jana Brezinova, PhD, Halka Lhotska, Karla Svobodova, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Zdenek Krejcik, PhD, Monika Belickova, PhD, Magda Siskova, MD, Anna Jonasova, MD, Radana Neuwirtova, MD PhD As. Prof., Jana Zmolikova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 859.

https://doi.org/10.1182/blood.V124.21.859.859

Published: 2014

Journal Articles

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

Monika Belickova, Jitka Vesela, Anna Jonasova, MD, Eliska Stara, Barbora Planetova, Zuzana Zemanova, Jana Brezinova, Dana Mikulenkova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 4630.

https://doi.org/10.1182/blood.V124.21.4630.4630

Published: 2014

Journal Articles

Defect in B Cell Production Driven By GATA2 Mutation Results in Their Absolute Reduction and Mature Phenotype in Pediatric Patients

Michaela Novakova, Ales Janda, Marcin W Wlodarski, Martina Sukova, Vit Campr, Marketa Kubricanova Zaliova, Eva Fronkova, Elena Vodickova, Ondrej Zapletal, Jan Blatny, Katerina Lejhancova, Dagmar Pospisilova, Zdena Cerna, Tomas Kuhn, Zuzana Zemanova, Jan Trka, Ondrej Hrusak, Jan Stary, Ester Mejstrikova

Blood (2014) 124 (21): 2746.

https://doi.org/10.1182/blood.V124.21.2746.2746

Published: 2014

Journal Articles

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

Jana Brezinova, PhD, Iveta Sarova, PhD, Halka Lhotska, Sarka Ransdorfova, PhD, Silvia Izakova, Karla Svobodova, Jana Markova, Zuzana Zemanova, Ass. Prof.,PhD, Jaroslav Cermak, MD PhD As. Prof., Anna T. Jonasova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5596.

https://doi.org/10.1182/blood.V124.21.5596.5596

Published: 2014

Journal Articles

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Radana Neuwirtova, MD PhD As. Prof., Zuzana Zemanova, Jana Brezinova, PhD, Pavel Dvorak, MD, Ota Fuchs, PhD, Martin Vostry, Anna T Jonasova, MD, Jaroslav Cermak, MD PhD As. Prof., Dana Sponerova, MD, Zuzana Maskova, MD, Libor Cervinek, MD PhD, Vera Vozobulova, MD, Eva Polonyova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5626.

https://doi.org/10.1182/blood.V124.21.5626.5626

Published: 2014

NARROW

SF3B1 Gene Mutations and Their Significance for Patients with Myelodysplastic Neoplasms (MDS)

First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Why Patients with 5q- Syndrome Have Thrombocythemia?

Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

Defect in B Cell Production Driven By GATA2 Mutation Results in Their Absolute Reduction and Mature Phenotype in Pediatric Patients

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

The Good Prognosis and Positive Response to the Therapy of Patients with Two Unrelated Clones Del(5q) and Trisomy 8 Does Not Differ to That of the 5q- Syndrome. This Is in Contrast to the Bad Prognosis of Patients with the Same Chromosomal Aberrations in One Clone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only